fig7

Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel

Figure 7. Effect of the cabazitaxel ritonavir combination in the docetaxel-resistant DU-145DOC10 cell line in the 3D clonogenic assay. (A) Concentration-effect curve showing a decrease in the cabazitaxel IC50 from 1.5 to 0.6 nM in the presence of 10 μM ritonavir; (B) Bliss Modeled T/C analysis shows synergistic effects at 10 μM ritonavir when combined with cabazitaxel concentrations of 1 and 3.16 nM.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/